Altman Advisors Inc. Purchases 183406 Shares of BlackRock, Inc. (NYSE:BLK)

Altman Advisors Inc. grew its position in shares of BlackRock, Inc. (NYSE:BLK) by 3,276.3% during the second quarter, according to its most recent …

BlackRock logoAltman Advisors Inc. grew its position in shares of BlackRock, Inc. (NYSE:BLK) by 3,276.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 189,004 shares of the asset manager’s stock after purchasing an additional 183,406 shares during the quarter. BlackRock makes up 2.0% of Altman Advisors Inc.’s holdings, making the stock its 20th biggest holding. Altman Advisors Inc. owned approximately 0.12% of BlackRock worth $2,140,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in BLK. Summit Trail Advisors LLC boosted its stake in shares of BlackRock by 53,902.3% during the first quarter. Summit Trail Advisors LLC now owns 1,274,454 shares of the asset manager’s stock valued at $1,274,000 after purchasing an additional 1,272,094 shares in the last quarter. FIL Ltd boosted its stake in shares of BlackRock by 386.0% during the first quarter. FIL Ltd now owns 322,223 shares of the asset manager’s stock valued at $174,555,000 after purchasing an additional 255,927 shares in the last quarter. BlackRock Inc. boosted its stake in shares of BlackRock by 2.6% during the first quarter. BlackRock Inc. now owns 7,447,936 shares of the asset manager’s stock valued at $4,034,698,000 after purchasing an additional 192,139 shares in the last quarter. Cornerstone Wealth Management LLC acquired a new stake in shares of BlackRock during the second quarter valued at about $377,000. Finally, Bessemer Group Inc. boosted its stake in shares of BlackRock by 6,346.5% during the second quarter. Bessemer Group Inc. now owns 183,724 shares of the asset manager’s stock valued at $91,685,000 after purchasing an additional 180,874 shares in the last quarter. 84.12% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently commented on the company. JPMorgan Chase & Co. reissued a “focus list” rating and set a $547.00 price target on shares of BlackRock in a research note on Monday, July 2nd. Keefe, Bruyette & Woods raised BlackRock from a “market perform” rating to an “outperform” rating and set a $590.00 price target on the stock in a research note on Friday, July 13th. Goldman Sachs Group cut their price target on BlackRock to $570.00 and set a “buy” rating on the stock in a research note on Tuesday, July 17th. ValuEngine lowered BlackRock from a “buy” rating to a “hold” rating in a research note on Friday, June 15th. Finally, Deutsche Bank cut their price target on BlackRock from $570.00 to $561.00 and set a “buy” rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $594.25.

BlackRock stock opened at $474.15 on Friday. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $76.71 billion, a P/E ratio of 20.98, a P/E/G ratio of 1.49 and a beta of 1.61. BlackRock, Inc. has a one year low of $408.62 and a one year high of $594.52.

BlackRock (NYSE:BLK) last posted its quarterly earnings data on Monday, July 16th. The asset manager reported $6.66 EPS for the quarter, topping the Zacks’ consensus estimate of $6.55 by $0.11. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.58 billion. BlackRock had a return on equity of 13.20% and a net margin of 38.97%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm earned $5.24 earnings per share. equities analysts predict that BlackRock, Inc. will post 27.71 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 24th. Investors of record on Friday, September 7th will be paid a $3.13 dividend. This is a positive change from BlackRock’s previous quarterly dividend of $2.88. This represents a $12.52 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date of this dividend is Thursday, September 6th. BlackRock’s payout ratio is currently 50.97%.

In other BlackRock news, insider Jeff A. Smith sold 166 shares of BlackRock stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $546.13, for a total value of $90,657.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William E. Ford bought 1,000 shares of the stock in a transaction on Thursday, August 2nd. The stock was acquired at an average price of $467.92 per share, with a total value of $467,920.00. Following the completion of the acquisition, the director now owns 5,400 shares of the company’s stock, valued at approximately $2,526,768. The disclosure for this purchase can be found here. 1.75% of the stock is owned by insiders.

BlackRock Company Profile

BlackRock, Inc is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.

Recommended Story: Investing in Growth Stocks

Institutional Ownership by Quarter for BlackRock (NYSE:BLK)

Receive News & Ratings for BlackRock Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BlackRock and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Purchases New Holdings in Cardlytics Inc (NASDAQ:CDLX)

BlackRock Inc. acquired a new position in Cardlytics Inc (NASDAQ:CDLX) in the 1st quarter, according to its most recent 13F filing with the Securities …

Cardlytics logoBlackRock Inc. acquired a new position in Cardlytics Inc (NASDAQ:CDLX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 233,836 shares of the company’s stock, valued at approximately $3,420,000. BlackRock Inc. owned approximately 1.17% of Cardlytics at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CDLX. Frontier Capital Management Co. LLC purchased a new position in Cardlytics during the first quarter valued at approximately $148,000. Wells Fargo & Company MN acquired a new stake in shares of Cardlytics during the first quarter worth $305,000. Dean Capital Investments Management LLC acquired a new stake in shares of Cardlytics during the first quarter worth $438,000. Northern Trust Corp acquired a new stake in shares of Cardlytics during the first quarter worth $840,000. Finally, Kornitzer Capital Management Inc. KS acquired a new stake in shares of Cardlytics during the first quarter worth $892,000. Hedge funds and other institutional investors own 49.41% of the company’s stock.

A number of research analysts recently issued reports on the stock. Bank of America restated a “hold” rating and set a $22.00 target price on shares of Cardlytics in a research report on Friday. KeyCorp decreased their price objective on shares of Cardlytics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Gabelli reaffirmed a “buy” rating on shares of Cardlytics in a research note on Monday, April 23rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $24.00.

NASDAQ CDLX opened at $20.62 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $401.64 million and a P/E ratio of -2.57. Cardlytics Inc has a 12 month low of $11.10 and a 12 month high of $25.71.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Tuesday, August 14th. The company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.32. The company had revenue of $35.57 million during the quarter, compared to analysts’ expectations of $34.89 million. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. research analysts forecast that Cardlytics Inc will post -1.97 EPS for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company’s platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: Price to Earnings Ratio (PE) Basics

Institutional Ownership by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cardlytics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Invests $3.41 Million in WillScot Corp (NASDAQ:WSC)

BlackRock Inc. acquired a new position in WillScot Corp (NASDAQ:WSC) in the 1st quarter, according to its most recent 13F filing with the Securities …

WillScot logoBlackRock Inc. acquired a new position in WillScot Corp (NASDAQ:WSC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 249,946 shares of the company’s stock, valued at approximately $3,412,000. BlackRock Inc. owned approximately 0.30% of WillScot at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Northern Trust Corp purchased a new position in WillScot in the first quarter valued at $567,000. Wells Fargo & Company MN acquired a new position in WillScot in the 4th quarter valued at about $600,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in WillScot in the 1st quarter valued at about $1,520,000. Hedge funds and other institutional investors own 37.15% of the company’s stock.

WSC has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of WillScot from a “hold” rating to a “sell” rating in a report on Thursday, May 10th. ValuEngine raised shares of WillScot from a “sell” rating to a “hold” rating in a research note on Tuesday, June 5th. Jefferies Financial Group assumed coverage on shares of WillScot in a research note on Monday, July 9th. They set a “buy” rating on the stock. Finally, Credit Suisse Group assumed coverage on shares of WillScot in a research report on Friday. They issued an “outperform” rating and a $20.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $16.50.

Shares of WSC opened at $16.00 on Friday. The company has a quick ratio of 0.80, a current ratio of 0.86 and a debt-to-equity ratio of 1.44. The stock has a market capitalization of $1.50 billion and a PE ratio of -4.13. WillScot Corp has a 52-week low of $9.45 and a 52-week high of $17.70.

WillScot (NASDAQ:WSC) last posted its earnings results on Tuesday, August 7th. The company reported $0.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.04. The business had revenue of $140.33 million for the quarter, compared to analysts’ expectations of $144.55 million. equities research analysts forecast that WillScot Corp will post 0.07 EPS for the current fiscal year.

WillScot Profile

WillScot Corporation, through its subsidiaries, provides various specialty rental services in the United States, Canada, and Mexico. It is involved in the leasing and sale of mobile offices, modular buildings, and storage products. The company offers various modular space units, including panelized and stackable offices, single-wide modular space units, section modulars and redi-plex complexes, classrooms, container offices, and other modular spaces; and portable storage units, such as shipping containers with swing doors.

Featured Article: Closed-End Mutual Funds (CEFs)

Institutional Ownership by Quarter for WillScot (NASDAQ:WSC)

Receive News & Ratings for WillScot Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for WillScot and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Reduces Holdings in XOMA Corp (XOMA)

BlackRock Inc. trimmed its stake in XOMA Corp (NASDAQ:XOMA) by 5.5% during the first quarter, according to its most recent 13F filing with the …

XOMA logoBlackRock Inc. trimmed its stake in XOMA Corp (NASDAQ:XOMA) by 5.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 178,419 shares of the biotechnology company’s stock after selling 10,383 shares during the period. BlackRock Inc. owned approximately 2.14% of XOMA worth $3,609,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of XOMA. Gotham Asset Management LLC acquired a new position in XOMA during the fourth quarter worth about $267,000. Wells Fargo & Company MN raised its position in XOMA by 4,288.9% during the fourth quarter. Wells Fargo & Company MN now owns 8,295 shares of the biotechnology company’s stock worth $295,000 after acquiring an additional 8,106 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of XOMA in the fourth quarter valued at approximately $328,000. Jane Street Group LLC acquired a new position in shares of XOMA in the fourth quarter valued at approximately $355,000. Finally, Two Sigma Advisers LP acquired a new position in shares of XOMA in the fourth quarter valued at approximately $464,000. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of XOMA from a “sell” rating to a “buy” rating and set a $27.00 price objective for the company in a research report on Wednesday, May 16th. HC Wainwright set a $49.00 price objective on shares of XOMA and gave the company a “buy” rating in a research report on Thursday, May 10th. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of XOMA in a report on Wednesday, August 8th. Cowen restated a “hold” rating on shares of XOMA in a report on Thursday, May 10th. Finally, TheStreet upgraded shares of XOMA from a “d” rating to a “c-” rating in a research note on Tuesday, June 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. XOMA currently has a consensus rating of “Hold” and an average price target of $31.32.

XOMA traded down $1.59 during trading on Friday, hitting $15.82. 149,500 shares of the company’s stock were exchanged, compared to its average volume of 144,635. XOMA Corp has a 1 year low of $7.39 and a 1 year high of $37.25. The company has a quick ratio of 12.46, a current ratio of 12.46 and a debt-to-equity ratio of 3.06. The company has a market cap of $154.57 million, a P/E ratio of 16.14 and a beta of 2.64.

XOMA (NASDAQ:XOMA) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). XOMA had a return on equity of 379.39% and a net margin of 43.55%. The firm had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.57 million. research analysts anticipate that XOMA Corp will post -0.94 earnings per share for the current year.

XOMA Company Profile

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Read More: Earnings Per Share

Institutional Ownership by Quarter for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for XOMA and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Buys 127118 Shares of Genesis Healthcare Inc (NYSE:GEN)

BlackRock Inc. grew its position in Genesis Healthcare Inc (NYSE:GEN) by 5.8% during the 1st quarter, according to the company in its most recent …

Genesis Healthcare logoBlackRock Inc. grew its position in Genesis Healthcare Inc (NYSE:GEN) by 5.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,302,417 shares of the company’s stock after acquiring an additional 127,118 shares during the period. BlackRock Inc. owned about 1.44% of Genesis Healthcare worth $3,476,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of GEN. Schwab Charles Investment Management Inc. purchased a new position in shares of Genesis Healthcare in the first quarter valued at $153,000. Glassman Wealth Services purchased a new position in shares of Genesis Healthcare in the first quarter valued at $1,661,000. Millennium Management LLC purchased a new position in shares of Genesis Healthcare in the fourth quarter valued at $184,000. Finally, Renaissance Technologies LLC grew its position in Genesis Healthcare by 40.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,194,100 shares of the company’s stock worth $911,000 after buying an additional 346,400 shares in the last quarter. 19.21% of the stock is currently owned by institutional investors and hedge funds.

In other Genesis Healthcare news, Director David A. Reis sold 47,365 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $1.65, for a total transaction of $78,152.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 200,676 shares of company stock valued at $365,004. 58.10% of the stock is currently owned by corporate insiders.

GEN stock traded down $0.01 during mid-day trading on Friday, hitting $1.54. 674,100 shares of the stock were exchanged, compared to its average volume of 765,684. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of -2.61. Genesis Healthcare Inc has a 12 month low of $0.60 and a 12 month high of $2.86. The firm has a market cap of $259.89 million, a P/E ratio of -0.73 and a beta of 0.82.

Genesis Healthcare (NYSE:GEN) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.13). The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the prior year, the business posted ($0.70) earnings per share. research analysts expect that Genesis Healthcare Inc will post -1.26 EPS for the current fiscal year.

Several research firms recently commented on GEN. Cantor Fitzgerald restated a “buy” rating and set a $7.00 target price on shares of Genesis Healthcare in a research report on Tuesday, August 7th. ValuEngine cut Genesis Healthcare from a “buy” rating to a “hold” rating in a research report on Wednesday, July 18th. Finally, Stifel Nicolaus set a $2.00 target price on Genesis Healthcare and gave the stock a “hold” rating in a research report on Tuesday, April 24th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Genesis Healthcare has a consensus rating of “Hold” and a consensus price target of $3.25.

Genesis Healthcare Company Profile

Genesis Healthcare, Inc is a holding company, which engages in the provision of inpatient services through skilled nursing and assisted and senior living communites. It also offers rehabilitation and respiratory therapy services. It operates through the following segments: Inpatient, Rehabilitation Therapy, and Other Services.

Featured Story: Trading Penny Stocks

Institutional Ownership by Quarter for Genesis Healthcare (NYSE:GEN)

Receive News & Ratings for Genesis Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genesis Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts